Pandemic Crushes Uptake of Uptake of Peanut Immunotherapy
email article The peanut-powder oral treatment Palforzia became the first FDA-approved immunotherapy for food allergy in late January 2020. The peanut (Arachis Hypogaea) allergen powder-dnfp is designed to desensitize peanut allergies in children and adolescents, and prevent potentially life-threatening reactions. Within 6 weeks of its approval for use in children, age 4-17 years, most of the U.S. shut down due to the pandemic, and it was widely agreed that the timing of the immunotherapy's arrival on the U.S. market was less than optimal. A little over a year later, it is still unclear...
Source: medpagetoday.com
